Recruitment stopped early due to positive exploratory and efficacy outcomes ...

Cresemba is marketed in more than 70 countries. According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between January and December 2024 ...

The biopharmaceutical industry saw a strong start to 2025, despite ongoing uncertainty around the potential impact of US ...

We recently published a list of 10 Best Multibagger Stocks to Buy According to Billionaires. In this article, we are going to ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization ...

"Manufacturing these cutting-edge products inherently requires a workforce with enhanced knowledge and skills." ...

Leiden, the Netherlands Thursday, April 24, 2025, 10:00 Hrs [IST] ...

Company outlined potential for value creation driven by obe-cel across multiple B cell driven malignancies and autoimmune diseases, including acute lymphoblastic leukemia (ALL), lupus nephritis (LN) ...

Protalix BioTherapeutics' Chief Financial Officer Eyal Rubin plans to leave the company and has given his six months notice. Rubin is leaving to pursue other opportunities, Protalix said Wednesday.

Protagonist Therapeutics, Inc. (”Protagonist” or the “Company”) announced that an abstract was accepted for presentation at the Plenary Session at the American Society of Clinical Oncology (ASCO) ...

Disruptive conditions are typical in non-Western markets. The U.S. industry, thrown into a period of significant change as ...

Neumora Therapeutics, Inc.’s NMRA share price has surged by 10.34%, which has investors questioning if this is right time to sell.